A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Olorinab (Primary)
- Indications Abdominal pain
- Focus Adverse reactions
- Sponsors Arena Pharmaceuticals
- 17 May 2019 According to an Arena Pharmaceuticals media release, data from this study will be presented at the Digestive Disease Week (DDW).
- 08 Mar 2019 According to a Arena Pharmaceuticals media release, new data from the trial was presented at the 14th Congress of European Crohn's and Colitis Organisation (ECCO).
- 26 Sep 2018 Status changed from active, no longer recruiting to completed.